Articles tagged with Type 1 Diabetes
A Medical College of Georgia bioinformatics expert has received a $15 million NIH grant to continue operating the Coordinating and Bioinformatics Unit. The grant will support the development of animal models for diabetic complications, including cardiovascular disease and kidney damage.
A clinical trial shows that islet transplantation using the Edmonton Protocol can dramatically benefit certain patients with severe complications of Type 1 diabetes. The procedure has promising implications for treating this autoimmune disease, which affects an estimated 21 million Americans.
A multicenter clinical trial confirmed the Edmonton Protocol's ability to safely promote long-term stabilization of blood sugar levels in 'brittle' diabetes patients, with some achieving insulin independence. Investigators also reported improved measures of blood glucose control and reversal of hypoglycemic unawareness.
The Edmonton Protocol clinical trial demonstrates islet transplantation as a promising procedure for managing severe Type 1 Diabetes, achieving insulin independence in 44% of recipients and improved blood sugar control. However, long-term sustainability varies, highlighting the need for continued research into this therapy.
A six-year study found high progression rates of diabetic retinopathy in African Americans with type 1 diabetes, linked to poor glycemic control and high blood pressure. The study highlights the need for improved medical care and regular eye exams to detect vision-threatening diabetic retinopathy.
Researchers found that cystic fibrosis patients develop unique diabetes due to differences in insulin-producing cell function, rather than pancreas destruction. This discovery may help improve understanding of other forms of diabetes and work towards a cure.
Researchers at the University at Buffalo are part of a global effort to prevent type 1 diabetes through a $172 million grant from the National Institutes of Health. The project aims to identify 100,000 individuals at risk and test interventions to halt the onset of the disease.
Dr. Brownlee, a leading researcher in type 1 diabetes, has been awarded the prestigious JDRF Scholar Award to pursue innovative research directions. He aims to develop strategies to reduce susceptibility to diabetic complications through his studies on hyperglycemic memory and free radical production.
A 25-year study analyzing over 4,000 young people with Type 1 diabetes found clusters of cases at specific geographical locations and time intervals. The results suggest that infections may be triggering the condition in genetically susceptible individuals.
Researchers have identified a protein peptide that regulates the immune system and prevents autoimmune disease in Type 1 diabetes. The peptide, p277, stimulates regulatory T cells to produce anti-inflammatory substances, weakening the immune response.
Researchers found that 48% of participants reported no or very little microvascular complications, and that some patients still have residual islet function. The study suggests that many patients with long-term type 1 diabetes may have some residual insulin production, paving the way for new treatments.
A long-term study of DCCT participants found no cognitive impairment from severe hypoglycemic reactions, supporting the safety of intensive diabetes therapy. Higher A1C readings were associated with a decline in motor speed and psychomotor efficiency, but not other cognitive domains.
A large study found that regular physical activity is associated with better glucose control and lower body mass index in children with type 1 diabetes. The research analyzed data from over 19,000 patients and found that increased physical activity was linked to lower HbA1c levels and improved glycemic control.
Researchers used adeno-associated virus to insert genes for interleukin-4 (IL-4) or interleukin-10 (IL-10) into insulin-producing beta cells, preventing hyperglycemia in non-obese diabetic mice. Gene therapy shows promise as a viable method for preventing type 1 diabetes in genetically at-risk individuals.
A 30-year study published in the journal Diabetes found that type 1 diabetics showed improved mortality and morbidity rates for certain complications, but cardiovascular disease rates remained unchanged. The study suggests that focusing solely on blood-glucose control is insufficient to prevent long-term complications of type 1 diabetes.
Researchers at La Jolla Institute for Immunology have made a major finding on a potential cure for type 1 diabetes by combining two therapies, producing better efficacy and longer-lasting results in preclinical trials. The combination therapy is being planned to begin human clinical trials later this year.
Researchers found a synergistic combination of a low-dose CD3 antibody and proinsulin peptide to reverse recent-onset type 1 diabetes in mice, promoting pancreatic beta cell regeneration. This approach may hold great potential for the treatment of individuals with recent-onset type 1 diabetes.
Researchers develop a combination therapy that reverses recent-onset type 1 diabetes in mice by inducing regulatory T cells to shield insulin-producing cells from autoimmune destruction. The therapy, which combines an oral and intranasal treatment, shows greater efficacy than individual treatments alone.
Researchers found that new islet cells are host-derived, not from donor spleen cells, and that beta-cell growth was permitted when autoimmunity was suppressed. The study suggests that CFA alone may be effective in treating type 1 diabetes without the need for donor spleen cells.
A University of Calgary bioengineering team has successfully grown insulin-producing cells in a lab, which could lead to the production of human tissue for transplantation. The breakthrough brings the team one step closer to addressing the serious condition that requires multiple daily insulin injections.
A study published in Diabetes Care found that tight blood glucose control can reduce the risk of nerve problems and foot amputations in diabetics. The study involved 1,441 people with Type 1 diabetes who had controlled their blood sugar tightly for at least five years.
A worldwide study is screening 220,800 healthy babies for genes that increase risk of developing type 1 diabetes. The researchers aim to identify environmental triggers that determine the risks for the disease.
Research suggests that obesity is linked to accelerated type I diabetes onset in patients with severely compromised pancreatic beta-cell function. Low birth weight also appears to be a contributing factor, with advanced age at diagnosis observed as birth weight decreased.
Researchers detected lower gray matter density in brains of patients with Type 1 diabetes, associated with poorer glycemic control and depression. The study opens up new approaches to understanding the central nervous system in diabetes.
A detailed study of the Major Histocompatibility Complex (MHC) region reveals a region of stability that may have provided protection against infection and disease. The study found over 300 amino acid changing variants, strong candidates for functional studies to understand the role of variation in MHC-associated disease.
A long-term study of patients with type 1 diabetes found that early and aggressive treatment, including insulin pumps and lifestyle interventions, significantly lowered the risk of serious cardiovascular events. This approach was associated with a 58% reduction in cardiovascular risks compared to conventional blood glucose control.
Research shows that tight glucose control significantly reduces heart disease and damage to the eyes, nerves, and kidneys in people with type 1 diabetes. The study found a 42% lower risk of cardiovascular events and a 58% lower risk of serious events like heart attacks or strokes.
Research by Corbett et al. reveals that islet cells are susceptible to necrosis when exposed to interleukin-1, a cytokine that triggers b-cell release of HMGB1. This process contributes to the development of diabetes.
Researchers developed a new approach to predict type 1 diabetes risk by combining older and newer methods, identifying a specific protein marker associated with rapid progression. The study found that individuals positive for this marker have an 80% risk of developing the disease after just 6.7 years.
The study found that the overall incidence of ESRD among type 1 diabetes patients is lower than previously reported. Patients diagnosed at a younger age and in later years had a smaller risk of developing ESRD. The risk of death increased with age, but patients diagnosed in the 1970s had a significantly lower risk of dying.
A new method to create a reversibly immortalized beta-cell line offers significant progress in developing an effective treatment for type 1 diabetes. The breakthrough, achieved by manipulating human beta-cells, has successfully controlled blood sugar levels in diabetic mice for over 30 weeks.
Researchers developed a novel MRI strategy to visualize inflammatory lesions in the pancreas that cause type-1 diabetes. This new approach provides preclinical data on mouse models, guiding the application of an in vivo MRI technique to patients with autoimmune diabetes.
A new imaging technology has shown promise in detecting pancreatic inflammation in type 1 diabetes, allowing for early prediction of disease progression and response to treatment. The technique uses magnetic nanoparticles and MRI to identify inflamed pancreatic islets, potentially reducing the need for invasive biopsies.
A new clinical trial has shown that the oral treatment RBX may reduce the risk of moderate vision loss caused by macular edema in patients with type 1 or type 2 diabetes. The study, led by Joslin Diabetes Center, evaluated the safety and effect of RBX on retinopathy progression and visual loss.
A new study found that diabetic patients are at higher risk for developing respiratory tract, skin and mucous membrane, and urinary tract infections. The odds were significantly higher for both type 1 and type 2 diabetic patients compared to non-diabetic controls.
Researchers found teen-age boys with Type 1 diabetes have significantly higher intima-media thickness than those without the disease, indicating greater atherosclerosis progression. Smoking and poor glucose control are key risk factors for cardiovascular disease in this population.
A North Carolina woman has successfully undergone an experimental islet cell transplant procedure, allowing her to become insulin-free. The procedure, performed at Carolinas Medical Center, is still in its early stages but holds promise for millions of people with Type 1 diabetes.
A study found that introducing gluten-containing foods to infants at 1-3 months old significantly increased the risk of developing celiac disease, compared to exposure between 4-6 months. The findings suggest that early exposure to gluten may trigger an immune response in genetically predisposed children.
Researchers at Joslin Diabetes Center have identified genetic regions involved in autoimmune diseases, including type 1 diabetes. The study found a chromosomal region where T-cells were given the green light to attack beta cells, leading to insulitis and later type 1 diabetes.
Researchers found that the MIF gene is crucial for the development of type 1 diabetes. Specially bred mice without the gene failed to develop diabetes compared to those with it. The finding provides proof of concept for blocking the formation of this protein as a promising approach to fighting diabetes.
Researchers at Northwell Health's Institute for Medical Research have identified a crucial gene in type 1 diabetes development, which triggers the immune system to attack and kill beta cells. Blocking this protein may halt the harmful process and allow remaining beta cells to produce insulin.
Researchers successfully transplanted islets from a single donor pancreas into eight women with type 1 diabetes, achieving insulin independence and freedom from hypoglycemia. The trial resulted in superior glycemic control in four of five recipients with sustained insulin independence.
A study published in Diabetologia found that higher levels of protein adiponectin are associated with a lower risk of coronary artery disease (CAD), even independent of conventional risk factors. The study showed a remarkable 63% reduction in CAD risk for each 6.3 microgram per milliliter increase in serum adiponectin levels.
The Genetics of Kidneys in Diabetes (GoKinD) collection provides nearly 10,000 DNA and clinical data samples from adults with type 1 diabetes in the US and Canada. The resource aims to study genes linked to kidney disease and diabetes.
The study aims to identify genetic markers that can predict the onset of type 1 diabetes. The researchers plan to analyze the human genome, messenger RNA, and proteins to find reliable predictors of the disease, which may lead to new treatments and a potential cure.
A study by Joslin Diabetes Center found that youth ages 8-18 with type 1 diabetes were more likely to monitor their blood glucose levels when playing a guessing game on a wireless-equipped personal digital assistant. The study showed an increase in diabetes knowledge and fewer episodes of hyperglycemia among participants.
Researchers at Northwestern University are developing novel biomaterials and imaging techniques to improve the survival and function of transplanted islet cells in patients with type 1 diabetes. The grant will fund efforts to create microenvironments favorable for islet survival and function via controlled delivery of biological factors.
Researchers at Joslin Diabetes Center have developed a new imaging technology using magnetic resonance imaging to detect early signs of type 1 diabetes. The technology tracks miniscule magnetic nanoparticles leaking from the blood vessels of the pancreas, allowing for non-invasive monitoring of the disease's progression.
Researchers at Baylor College of Medicine have discovered a new gene associated with an increased risk of developing type 1 diabetes. SUMO-4 plays a key role in regulating the immune system and has been found to prolong the inflammatory response when mutated, leading to cell death and destruction of insulin-producing cells.
The study found that increasing PPAR-gamma activity in dendritic cells can activate NKT cells specifically, which may slow down the process of type 1 diabetes. Researchers believe that modulating CD1d expression and NKT cell activation could provide insight into how to combat autoimmunity.
Researchers found a natural mutation of the SUMO-4 gene, which regulates immune system activity, to be a major contributor to type 1 diabetes. The mutation increases the immune system's reactivity to environmental triggers, leading to an autoimmune response that attacks the patient's own tissue.
Researchers studied insulitis lesions in genetically engineered mice and discovered that inducible co-stimulator (ICOS) plays a crucial role in keeping insulitis respectful. Blocking ICOS disrupts the balance between T effector and regulatory cells, leading to diabetes progression.
Researchers discover a new strategy to combat type 1 diabetes by blocking the interaction of RAE-1 with its immune receptor, NKG2D. The treatment has shown complete effectiveness in preventing diabetes development in mice and promises potential as an effective human treatment.
Researchers at Rockefeller University have discovered that dendritic cells can stimulate the growth of suppressor T cells, which turn off the immune response and rescue islet cells from destruction. This breakthrough could lead to a prevention of Type 1 diabetes in humans.
Researchers found that natural killer cells are associated with destructive insulitis and beta cell destruction, suggesting a potential new target for halting or slowing disease progression. The study's findings have implications for understanding the complex interactions between immune cells and the development of type 1 diabetes.
A new protein form, liCTLA-4, found to inhibit T cell responses and reduce activation. Increased expression of liCTLA-4 in resistant mice strains suggests its role in preventing T cell-mediated autoimmune diseases like type 1 diabetes.
UVa researchers have identified a gene, Stat-4, that plays a key role in the development of type 1 diabetes. Disrupting this gene may help prevent the disease, and a new anti-inflammatory compound, Lisofylline (LSF), has shown promise in inhibiting its activation.
A synthetic compound called ISO-1 appears to work by blocking inflammation and protecting mice from developing type 1 diabetes. The researchers believe it could be developed into an oral drug that provides long-lasting protection for young people.
Researchers have successfully treated individuals with Type 1 diabetes using a single infusion of islet cells, with recipients maintaining insulin independence for over one to three years. The new treatment approach uses optimized recipient immunosuppression and a novel anti-CD3 monoclonal antibody.
Researchers develop gene therapy to enhance islet cell function and survival after transplantation. The technique uses a growth factor DNA to induce cell division, improving insulin production and glucose control in rat models. However, standard immunosuppression drug therapy may be harmful, inducing insulin resistance and diabetes.